NCT00331071View on ClinicalTrials.gov

Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks

CompletedOBSERVATIONAL
Enrollment

334

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
ContraceptionFemale Contraception
Interventions
DRUG

Monophasic or triphasic Oral contraceptive tablet

fourth week is patch free

DRUG

Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE

worn for 1 week and replaced for 3 consecutive weeks

All Listed Sponsors
collaborator

Boston Collaborative Drug Surveillance Program

OTHER

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00331071 - Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks | Biotech Hunter | Biotech Hunter